{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:18:48Z","timestamp":1792930728792,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.7759\/cureus.98153","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T16:05:46Z","timestamp":1764518746000},"source":"Crossref","is-referenced-by-count":2,"title":["The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care"],"prefix":"10.7759","author":[{"given":"Angela D","family":"Mazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007","article-title":"Hashimoto thyroiditis: clinical and diagnostic criteria","volume":"13","author":"Caturegli P","year":"2014","unstructured":"Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014, 13:391-7. 10.1016\/j.autrev.2014.01.007","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1614624","article-title":"Graves' disease","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Heged\u00fcs L. Graves' disease. N Engl J Med. 2017, 376:185. 10.1056\/NEJMc1614624","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi B","year":"2019","unstructured":"Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev. 2019, 40:789-824. 10.1210\/er.2018-00163","journal-title":"Endocr Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112841","article-title":"NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management","volume":"20","author":"Lonardo A","year":"2019","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci. 2019, 20:2841. 10.3390\/ijms20112841","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0797","article-title":"Studies of insulin resistance in patients with clinical and subclinical hypothyroidism","volume":"160","author":"Maratou E","year":"2009","unstructured":"Maratou E, Hadjidakis DJ, Kollias A, et al.. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009, 160:785-90. 10.1530\/EJE-08-0797","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9395-7","article-title":"Thyroid dysfunction and kidney disease: an update","volume":"18","author":"Iglesias P","year":"2017","unstructured":"Iglesias P, Bajo MA, Selgas R, D\u00edez JJ. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disord. 2017, 18:131-44. 10.1007\/s11154-016-9395-7","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3094642","article-title":"Anti-Inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee YS","year":"2016","unstructured":"Lee YS, Jun HS. Anti-Inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016, 2016:3094642. 10.1155\/2016\/3094642","journal-title":"Mediators Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00521","article-title":"Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases","volume":"8","author":"Fr\u00f6hlich E","year":"2017","unstructured":"Fr\u00f6hlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017, 8:521. 10.3389\/fimmu.2017.00521","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1719","article-title":"Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis","volume":"95","author":"Figueroa-Vega N","year":"2010","unstructured":"Figueroa-Vega N, Alfonso-P\u00e9rez M, Benedicto I, S\u00e1nchez-Madrid F, Gonz\u00e1lez-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2010, 95:953-62. 10.1210\/jc.2009-1719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2012.751981","article-title":"Lower proportions of CD4+CD25(high) and CD4+FoxP3, but not CD4+CD25+CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases","volume":"46","author":"Bossowski A","year":"2013","unstructured":"Bossowski A, Moniuszko M, D\u0105browska M, et al.. Lower proportions of CD4+CD25(high) and CD4+FoxP3, but not CD4+CD25+CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases. Autoimmunity. 2013, 46:222-30. 10.3109\/08916934.2012.751981","journal-title":"Autoimmunity"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldr030","article-title":"The epidemiology of thyroid disease","volume":"99","author":"Vanderpump MP","year":"2011","unstructured":"Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011, 99:39-51. 10.1093\/bmb\/ldr030","journal-title":"Br Med Bull"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce EN","year":"2003","unstructured":"Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003, 348:2646-55. 10.1056\/NEJMra021194","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli A","year":"2015","unstructured":"Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015, 14:174-80. 10.1016\/j.autrev.2014.10.016","journal-title":"Autoimmun Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves' disease","volume":"84","author":"Bartalena L","year":"2016","unstructured":"Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016, 84:115-20. 10.1111\/cen.12688","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series","volume":"18","author":"Ferrari SM","year":"2019","unstructured":"Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev. 2019, 18:287-92. 10.1016\/j.autrev.2018.10.001","journal-title":"Autoimmun Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0423","article-title":"Increases of the Th1\/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease","volume":"19","author":"Nanba T","year":"2009","unstructured":"Nanba T, Watanabe M, Inoue N, Iwatani Y. Increases of the Th1\/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease. Thyroid. 2009, 19:495-501. 10.1089\/thy.2008.0423","journal-title":"Thyroid"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al.. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017, 376:1748-61. 10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas RS","year":"2008","unstructured":"Douglas RS, Naik V, Hwang CJ, et al.. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008, 181:5768-74. 10.4049\/jimmunol.181.8.5768","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506050-00003","article-title":"Pretibial myxedema: pathophysiology and treatment options","volume":"6","author":"Fatourechi V","year":"2005","unstructured":"Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005, 6:295-309. 10.2165\/00128071-200506050-00003","journal-title":"Am J Clin Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can J","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014, 38:784-93. 10.1038\/ijo.2013.162","journal-title":"Int J Obes (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan AE","year":"2014","unstructured":"Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J, O'Shea D. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014, 57:781-4. 10.1007\/s00125-013-3145-0","journal-title":"Diabetologia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5783639","article-title":"The glucagon-like peptide-1 receptor agonist exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of TNF-\u03b1 expression in macrophages","volume":"2018","author":"Shen WR","year":"2018","unstructured":"Shen WR, Kimura K, Ishida M, et al.. The glucagon-like peptide-1 receptor agonist exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of TNF-\u03b1 expression in macrophages. J Immunol Res. 2018, 2018:5783639. 10.1155\/2018\/5783639","journal-title":"J Immunol Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang JY","year":"2023","unstructured":"Wang JY, Wang QW, Yang XY, et al.. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol (Lausanne). 2023, 14:1085799. 10.3389\/fendo.2023.1085799","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000501895","article-title":"The effect of exenatide on thyroid-stimulating hormone and thyroid volume","volume":"8","author":"Sencar ME","year":"2019","unstructured":"Sencar ME, Sakiz D, Calapkulu M, et al.. The effect of exenatide on thyroid-stimulating hormone and thyroid volume. Eur Thyroid J. 2019, 8:307-11. 10.1159\/000501895","journal-title":"Eur Thyroid J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0257","article-title":"Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","volume":"12","author":"Lisco G","year":"2023","unstructured":"Lisco G, De Tullio A, Disoteo O, et al.. Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?. Endocr Connect. 2023, 12:e230257. 10.1530\/EC-23-0257","journal-title":"Endocr Connect"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0530","article-title":"Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review","volume":"34","author":"Espinosa De Ycaza AE","year":"2024","unstructured":"Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review. Thyroid. 2024, 34:403-18. 10.1089\/thy.2023.0530","journal-title":"Thyroid"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi N","year":"2011","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011, 11:85-97. 10.1038\/nri2921","journal-title":"Nat Rev Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/nri1350","article-title":"The weight of leptin in immunity","volume":"4","author":"La Cava A","year":"2004","unstructured":"La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004, 4:371-9. 10.1038\/nri1350","journal-title":"Nat Rev Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg H","year":"2006","unstructured":"Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006, 6:772-83. 10.1038\/nri1937","journal-title":"Nat Rev Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.10.015","article-title":"Leptin resistance and diet-induced obesity: central and peripheral actions of leptin","volume":"64","author":"S\u00e1inz N","year":"2015","unstructured":"S\u00e1inz N, Barrenetxe J, Moreno-Aliaga MJ, Mart\u00ednez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism. 2015, 64:35-46. 10.1016\/j.metabol.2014.10.015","journal-title":"Metabolism"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S340","article-title":"Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin","volume":"32 Suppl 2","author":"Esteve E","year":"2009","unstructured":"Esteve E, Ricart W, Fern\u00e1ndez-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009, 32 Suppl 2:S362-7. 10.2337\/dc09-S340","journal-title":"Diabetes Care"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0049","article-title":"Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity","volume":"31","author":"Ganesh BB","year":"2011","unstructured":"Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011, 31:721-31. 10.1089\/jir.2011.0049","journal-title":"J Interferon Cytokine Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng CN","year":"2011","unstructured":"Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011, 121:2111-7. 10.1172\/JCI57132","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0395","article-title":"Alterations of the gut microbiota in Hashimoto\u2019s thyroiditis patients","volume":"28","author":"Zhao F","year":"2018","unstructured":"Zhao F, Feng J, Li J, et al.. Alterations of the gut microbiota in Hashimoto\u2019s thyroiditis patients. Thyroid. 2018, 28:175-86. 10.1089\/thy.2017.0395","journal-title":"Thyroid"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9467-y","article-title":"Gut microbiota and Hashimoto's thyroiditis","volume":"19","author":"Virili C","year":"2018","unstructured":"Virili C, Fallahi P, Antonelli A, Benvenga S, Centanni M. Gut microbiota and Hashimoto's thyroiditis. Rev Endocr Metab Disord. 2018, 19:293-300. 10.1007\/s11154-018-9467-y","journal-title":"Rev Endocr Metab Disord"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8291-x","article-title":"Leaky gut and autoimmune diseases","volume":"42","author":"Fasano A","year":"2012","unstructured":"Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol. 2012, 42:71-8. 10.1007\/s12016-011-8291-x","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0549-0","article-title":"Gut microbiota derived metabolites in cardiovascular health and disease","volume":"9","author":"Wang Z","year":"2018","unstructured":"Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 2018, 9:416-31. 10.1007\/s13238-018-0549-0","journal-title":"Protein Cell"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun H","year":"2024","unstructured":"Sun H, Shu J, Tang J, et al.. GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells. Immunology. 2024, 172:451-68. 10.1111\/imm.13784","journal-title":"Immunology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217743765","article-title":"Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats","volume":"243","author":"Zhang Q","year":"2018","unstructured":"Zhang Q, Xiao X, Zheng J, et al.. Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp Biol Med (Maywood). 2018, 243:34-44. 10.1177\/1535370217743765","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.01.053","article-title":"\"With a little help from my friends\" - the role of microbiota in thyroid hormone metabolism and enterohepatic recycling","volume":"458","author":"Virili C","year":"2017","unstructured":"Virili C, Centanni M. \"With a little help from my friends\" - the role of microbiota in thyroid hormone metabolism and enterohepatic recycling. Mol Cell Endocrinol. 2017, 458:39-43. 10.1016\/j.mce.2017.01.053","journal-title":"Mol Cell Endocrinol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen L","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, et al.. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010, 151:1473-86. 10.1210\/en.2009-1272","journal-title":"Endocrinology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser B","year":"2015","unstructured":"Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015, 28:391-402. 10.1038\/modpathol.2014.113","journal-title":"Mod Pathol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0233","article-title":"GLP-1 receptor agonist effects on normal and neoplastic pancreata","volume":"61","author":"Goggins M","year":"2012","unstructured":"Goggins M. GLP-1 receptor agonist effects on normal and neoplastic pancreata. Diabetes. 2012, 61:989-90. 10.2337\/db12-0233","journal-title":"Diabetes"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil GS","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006, 444:860-7. 10.1038\/nature05485","journal-title":"Nature"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg H","year":"2020","unstructured":"Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020, 17:387-8. 10.1038\/s41575-020-0316-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser N","year":"2014","unstructured":"Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014, 105:141-50. 10.1016\/j.diabres.2014.04.006","journal-title":"Diabetes Res Clin Pract"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha AR","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AA, et al.. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017, 66:1037-46. 10.1016\/j.jhep.2017.01.022","journal-title":"J Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1786559","article-title":"Effect of liraglutide on serum TSH levels in patients with NAFLD and its underlying mechanisms","volume":"2022","author":"Ye J","year":"2022","unstructured":"Ye J, Xu J, Wen W, Huang B. Effect of liraglutide on serum TSH levels in patients with NAFLD and its underlying mechanisms. Int J Clin Pract. 2022, 2022:1786559. 10.1155\/2022\/1786559","journal-title":"Int J Clin Pract"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.275","article-title":"Exenatide treatment reduces thyroid gland volume, but has no effect on the size of the thyroid nodules","volume":"16","author":"K\u00f6seo\u011flu D","year":"2020","unstructured":"K\u00f6seo\u011flu D, \u00d6zdemir Ba\u015fer \u00d6, Berker D, G\u00fcler S. Exenatide treatment reduces thyroid gland volume, but has no effect on the size of the thyroid nodules. Acta Endocrinol (Buchar). 2020, 16:275-9. 10.4183\/aeb.2020.275","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/biom14060687","article-title":"Implications of GLP-1 receptor agonist on thyroid function: a literature review of Its effects on thyroid volume, risk of cancer, functionality and TSH levels","volume":"14","author":"Capuccio S","year":"2024","unstructured":"Capuccio S, Scilletta S, La Rocca F, et al.. Implications of GLP-1 receptor agonist on thyroid function: a literature review of Its effects on thyroid volume, risk of cancer, functionality and TSH levels. Biomolecules. 2024, 14:687. 10.3390\/biom14060687","journal-title":"Biomolecules"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu W","year":"2022","unstructured":"Hu W, Song R, Cheng R, et al.. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022, 13:927859. 10.3389\/fendo.2022.927859","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier B","year":"2012","unstructured":"Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012, 97:121-31. 10.1210\/jc.2011-2407","journal-title":"J Clin Endocrinol Metab"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen LW","year":"2012","unstructured":"Madsen LW, Knauf JA, Gotfredsen C, et al.. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012, 153:1538-47. 10.1210\/en.2011-1864","journal-title":"Endocrinology"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas J","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, et al.. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014, 24:1670-751. 10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0345","article-title":"Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition","volume":"26","author":"Samuels MH","year":"2016","unstructured":"Samuels MH, Kolobova I, Smeraglio A, Peters D, Purnell JQ, Schuff KG. Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition. Thyroid. 2016, 26:347-55. 10.1089\/thy.2015.0345","journal-title":"Thyroid"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of Graves\u2019 thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly GJ","year":"2020","unstructured":"Kahaly GJ. Management of Graves\u2019 thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020, 105:3704-20. 10.1210\/clinem\/dgaa646","journal-title":"J Clin Endocrinol Metab"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline","volume":"100","author":"Stuenkel CA","year":"2015","unstructured":"Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015, 100:3975-4011. 10.1210\/jc.2015-2236","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430891-the-thyroid-twist-how-glp-1-agonists-are-influencing-autoimmune-thyroid-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T16:05:47Z","timestamp":1764518747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430891-the-thyroid-twist-how-glp-1-agonists-are-influencing-autoimmune-thyroid-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.98153","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}